Truist Securities Reiterates Buy on Amgen, Maintains $320 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas reiterates a Buy rating on Amgen (NASDAQ:AMGN) with a maintained price target of $320.
April 12, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities reaffirms a Buy rating on Amgen with a $320 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $320 price target by Truist Securities suggests a strong conviction in Amgen's stock performance. This analyst endorsement can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100